Shares of other companies:
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ABT Stock News and Mentions of Abbott Laboratories Stocktwits
Updated: April 29, 2024 (10:08)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Abbott Laboratories Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Abbott Laboratories (ABT).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Abbott Laboratories stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Abbott Laboratories (ABT)
April 28, 2024 (11:45) / "Motley Fool" (by Prosper Junior Bakiny)
2 Beaten-Down Dividend Stocks to Buy and Hold Forever
These companies aren't in danger of becoming has-beens.
In Article Trend: Somewhat-Bullish
April 28, 2024 (08:20) / "Motley Fool" (by Prosper Junior Bakiny)
Better Dividend Stock: AbbVie or Johnson & Johnson?
One thing is for sure: Dividend seekers can't go wrong with either.
In Article Trend: Somewhat-Bullish
April 27, 2024 (11:15) / "Motley Fool" (by Keith Speights)
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks.
In Article Trend: Somewhat-Bullish
April 25, 2024 (12:21) / "Zacks Commentary" (by Zacks Equity Research)
3 Diamond Hill Mutual Funds for Higher Returns
Invests in Diamond Hill mutual funds like DHLSX, DHLTX and DHLAX for diversified investment opportunities across various asset classes.
In Article Trend: Somewhat-Bullish
April 24, 2024 (19:53) / "CNBC" (by Kevin Stankiewicz)
Here's a rapid-fire update on all 33 portfolio stocks including our tech giants reporting this week
During the Investing Club's Monthly Meeting on Wednesday, Jim Cramer offered his updated thinking on the stocks in the portfolio.
In Article Trend: Neutral
April 23, 2024 (15:36) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.
In Article Trend: Somewhat-Bullish
April 19, 2024 (16:51) / "Investors Business Daily" (by IBD STAFF)
Stock Market Shows Bearish Action: Weekly Review
Stock Market Sells Off. Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
April 19, 2024 (12:30) / "Investors Business Daily" (by Investor's Business Daily)
Dexcom In Buy Zone After Launch Of Prescription-Free Diabetes Monitor; Earnings Due Next Week
Dexcom Stock Is In Buy Zone Ahead Of Earnings Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 18, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Global Radioimmunoassay Market to Grow at a Minimal CAGR of ~3% by 2030 | DelveInsight
The increasing need for radioimmunoassay is mainly driven by the rising occurrence of cancer, infectious diseases, and various other health conditions, along with a growing number of epidemics and pandemics and increasing health awareness.
In Article Trend: Neutral
April 18, 2024 (17:31) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Abbott Laboratories's Latest Options Trends - Abbott Laboratories ( NYSE:ABT )
Investors with significant funds have taken a bearish position in Abbott Laboratories ABT, a development that retail traders should be aware of. This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga.
In Article Trend: Somewhat-Bullish
April 17, 2024 (15:26) / "Fox Business News" (by Daniella Genovese)
Heart pumps tied to 14 deaths, hundreds of injuries are being recalled
Nearly 14,000 heart pumps tied to hundreds of injuries and more than a dozen deaths are being recalled, according to federal health officials.
In Article Trend: Neutral
April 17, 2024 (15:04) / "Zacks Commentary" (by Zacks Equity Research)
Q1 Earnings Review
Pre-market futures are up slightly at this hour. Markets look to rebound off a three-day losing streak on the S&P 500 and Nasdaq. the blue-chip Dow outperformed the field yesterday, closing +0.17%. Major indices are all lower over the past month, from -1.7% ( tech-heavy Nasdaq ) to -2.9% ( ...
In Article Trend: Neutral
April 17, 2024 (14:32) / "Zacks Commentary" (by Mark Vickery)
Markets Try to Shake Off April Blues
Late March highs -- including all-time S&P levels -- have given way to profit-taking and existential concerns.
In Article Trend: Neutral
April 17, 2024 (14:30) / "Benzinga" (by Globe Newswire)
Blood Collection Market size worth $ 14.76 Billion, Globally, by 2031 at 5.10% CAGR - Report By Verified Market Research®
Jersey City, New Jersey, April 17, 2024 ( GLOBE NEWSWIRE ) -- The Global Blood Collection Market is projected to grow at a CAGR of 5.10% from 2024 to 2031, according to a new report published by Verified Market Research®.
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:13) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Q1 Earnings Beat Estimates, Margins Contract
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
In Article Trend: Somewhat-Bullish
April 17, 2024 (14:07) / "Benzinga" (by Avi Kapoor)
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings - Abbott Laboratories ( NYSE:ABT ) , Edible Garden AG ( NASDAQ:EDBL )
U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.55% to 38,006.47 while the NASDAQ rose 0.24% to 15,903.38. The S&P 500 also rose, gaining, 0.40% to 5,071.74.
In Article Trend: Somewhat-Bullish
April 17, 2024 (12:46) / "CNBC" (by Jeff Marks)
We're buying a health-care stock that should be higher after reporting a strong quarter
It's the third time in recent weeks that we've added to our position in the medical device maker.
In Article Trend: Somewhat-Bullish
April 17, 2024 (12:42) / "Benzinga" (by Vandana Singh)
Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance - Abbott Laboratories ( NYSE:ABT )
Wednesday, Abbott Laboratories ABT reported first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beating the consensus of $9.88 billion. Reported sales increased by 2.2%, which includes the anticipated decline in COVID-19 testing-related revenue ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (11:52) / "Investors Business Daily" (by Investor's Business Daily)
Abbott Labs Jumps, Retreats On Q1 Beat, Shy Guidance
Abbott stock see-sawed early Wednesday after the giant health care company reported adjusted income of 98 cents a share on $10 billion in first-quarter sales. The Street projected earnings of 95 cents a share and $9.88 billion in sales, according to FactSet.
In Article Trend: Somewhat-Bullish
April 17, 2024 (11:09) / "Benzinga" (by Shanthi Rexaline)
S&P 500, Nasdaq Futures Point To Higher Open Today: What's Going On? - Invesco QQQ Trust, Series 1 ( NASDAQ:QQQ ) , SPDR S&P 500 ( ARCA:SPY )
U.S. stocks are priming for a firmer start on Wednesday, potentially striving to inflect higher from the weakness seen so far in April. As some bullish market watchers pointed out there could be an inflection from the second half of April, with earnings potentially serving as an upside catalyst.
In Article Trend: Neutral
April 17, 2024 (06:06) / "Benzinga" (by Avi Kapoor)
Investor Optimism Decreases; Dow Ends 6-Session Losing Streak - Abbott Laboratories ( NYSE:ABT ) , Bank of America ( NYSE:BAC )
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index remaining in the "Fear" zone on Tuesday. U.S. stocks closed mixed on Tuesday amid increased geopolitical concerns. The Dow Jones index, meanwhile, snapped its six-session losing streak.
In Article Trend: Somewhat-Bearish
April 17, 2024 (06:06) / "Benzinga" (by Avi Kapoor)
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday - Abbott Laboratories ( NYSE:ABT ) , U.S. Bancorp ( NYSE:USB )
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Abbott Laboratories ABT to report quarterly earnings at 95 cents per share on revenue of $9.88 billion before the opening bell, according to ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:30) / "Kiplinger" (by Joey Solitro)
Why Is UNH Stock Soaring After Earnings?
UnitedHealth Group ( UNH ) stock is soaring over 5% in Tuesday's session after the company beat both earnings and revenue estimates for its fiscal 2024 first quarter. UNH stock can certainly use the boost considering it was down 15% for the year-to-date heading into today's trading.
In Article Trend: Bullish
April 16, 2024 (14:56) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Hurt by Softness in BioPharma and Competition
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
April 16, 2024 (12:10) / "Forbes" (by Danielle Chemtob)
Daily: Samsung Overtakes Apple As iPhone Shipments Slump
Forbes Daily: Samsung overtakes Apple in smartphone shipments Forbes ...
In Article Trend: Neutral
April 16, 2024 (10:30) / "Forbes" (by Giacomo Tognini)
Inside The Collapse Of A Former Billionaire's Foundation For Low-Income Students
Healthcare Investor Shuts Down Scholarship Program Forbes ...
In Article Trend: Neutral
April 15, 2024 (08:14) / "The Financial Express"
Page 40320 of
Ambuja Realty Group has entered into the education sector, taking over Institute of Technology and Marine Engineering, although it would… Most human resource managers try to serenade the 18-25 year olds, the Generation Y, by either money or promise of…
In Article Trend: Neutral
April 14, 2024 (11:30) / "CNN" (by Bryan Mena)
Americans are savings less these days. Here's why and what that means | Business
Americans are saving less these days. Here's why and what that means ...
In Article Trend: Neutral
April 14, 2024 (05:23) / "Motley Fool" (by Alex Carchidi)
Is AbbVie a Millionaire Maker?
Everything is going according to plan, and more growth is on the way.
In Article Trend: Somewhat-Bullish
April 13, 2024 (03:33) / "PR Newswire" (by 360iResearch)
STD Testing Market Projected to Reach $14.11 billion by 2030 - Exclusive Report by 360iResearch
PUNE, India, April 12, 2024 /PRNewswire/ -- The report titled "STD Testing Market by Type ( Blood Tests, Lumbar Puncture, Swab Tests ) , Product Type ( Instruments, Reagents & Kits ) , Test Settings, Indication, End-user - Global Forecast 2024-2030" is now available on 360iResearch.com's ...
In Article Trend: Bullish
April 13, 2024 (00:57) / "Zacks Commentary" (by Shaun Pruitt)
3 Buy Rated Stocks to Consider as Earnings Approach
Several top-rated Zacks stocks are standing out before their first-quarter earnings report next week and here are three to consider.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:51) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Abbott Laboratories ( ABT ) in Q1 Earnings?
Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
In Article Trend: Somewhat-Bullish
April 12, 2024 (12:43) / "Benzinga" (by Avi Kapoor)
Jim Cramer Calls Cummins 'Terrific,' Recommends Selling This Chinese Auto Manufacturer - Abbott Laboratories ( NYSE:ABT ) , Cummins ( NYSE:CMI )
On CNBC's "Mad Money Lightning Round," Jim Cramer said he likes New Fortress Energy Inc. NFE, but "right now Wes Edens [co-founder of Fortress Investment Group and founder of New Fortress Energy] is kind of just hurt by the president."
In Article Trend: Somewhat-Bullish
April 11, 2024 (18:31) / "Benzinga" (by Benzinga Insights)
Abbott Laboratories Unusual Options Activity - Abbott Laboratories ( NYSE:ABT )
Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. Looking at options history for Abbott Laboratories ABT we detected 8 trades. If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:31) / "Zacks Commentary" (by Zacks Equity Research)
Medtronic's ( MDT ) Sphere-360 PFA Study Outcome Favorable
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
In Article Trend: Somewhat-Bullish
April 11, 2024 (10:15) / "Motley Fool" (by Prosper Junior Bakiny)
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
These companies provide stability, reliability, and passive income.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:10) / "Benzinga" (by Avi Kapoor)
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' - Abbott Laboratories ( NYSE:ABT ) , Emerson Electric ( NYSE:EMR )
On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories ABT over Penumbra, Inc. PEN. "I still fear it after the environmental damage. I am concerned that you can't really put a price on it," Cramer said when asked about Hawaiian Electric Industries, Inc.
In Article Trend: Neutral
April 9, 2024 (10:45) / "Motley Fool" (by Adam Spatacco)
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
In Article Trend: Somewhat-Bullish
April 9, 2024 (08:21) / "Motley Fool" (by Cory Renauer)
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:10) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Faces Low Testing Demand, Currency Headwinds
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:13) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services
T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services are part of the Zacks top Analyst Blog.
In Article Trend: Somewhat-Bullish
April 5, 2024 (20:55) / "Zacks Commentary" (by Sheraz Mian)
Top Analyst Reports for T-Mobile US, Abbott Laboratories & Palo Alto Networks
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW).
In Article Trend: Bullish
April 5, 2024 (13:52) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) Receives FDA's Approval for the TriClip TEER System
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
In Article Trend: Somewhat-Bullish
April 4, 2024 (08:47) / "Benzinga" (by Benzinga Neuro)
Is Your Smartphone The Future Of Heart Disease Detection? This Finnish Startup Thinks So
CardioSignal, a Finnish startup, has developed a system that uses smartphone motion sensors to detect heart disease. This innovation is a significant breakthrough in the health tech industry.
In Article Trend: Bullish
April 3, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Transformative Growth Expected In The Global Medical Equipment Market: Market Size To Reach $1,077 Billion By 2028 As Per The Business Research Company's Medical Equipment Global Market Report 2024
LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Medical Equipment Global Market Report 2024, the medical equipment market has witnessed robust growth in recent years, with the market size expected to reach $775.42 billion in 2024, reflecting a compound annual ...
In Article Trend: Somewhat-Bullish
April 3, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares U.S. Medical Devices ETF ( IHI ) ?
Sector ETF report for IHI ...
In Article Trend: Somewhat-Bullish
April 2, 2024 (17:00) / "Benzinga" (by Vandana Singh)
FDA Approves Abbott's Heart Valve Repair Device For Patients At Risk Of Complications/Death During Open-Heart Surgeries - Abbott Laboratories ( NYSE:ABT )
Tuesday, the FDA approved Abbott Laboratories' ABT first-of-its-kind TriClip transcatheter edge-to-edge repair ( TEER ) system that's specifically designed to treat tricuspid regurgitation ( TR ) , or a leaky tricuspid valve.
In Article Trend: Somewhat-Bullish
April 2, 2024 (15:18) / "Zacks Commentary" (by Zacks Equity Research)
Abbott's ( ABT ) i-STAT TBI Cartridge Receives FDA Approval
Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.
In Article Trend: Neutral
April 2, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Electroceuticals/Bioelectric Medicine Market is Expected to Reach $33.6 billion | MarketsandMarkets™
Chicago, April 02, 2024 ( GLOBE NEWSWIRE ) -- Electroceuticals/Bioelectric Medicine market in terms of revenue was estimated to be worth $23.9 billion in 2024 and is poised to reach $33.6 billion by 2029, growing at a CAGR of 7.0% from 2024 to 2029 according to a latest report published by ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (10:30) / "Benzinga" (by PRNewswire)
Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors - Elanco Animal Health ( NYSE:ELAN )
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated ELAN today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors ( ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (10:30) / "PR Newswire" (by Elanco Animal Health)
Elanco Appoints Two Animal Health Industry Executives, Kathy Turner and Craig Wallace, to its Board of Directors
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee
In Article Trend: Somewhat-Bullish
April 1, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Invesco Pharmaceuticals ETF ( PJP ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (08:30) / "Motley Fool" (by Prosper Junior Bakiny)
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations.
In Article Trend: Somewhat-Bullish
March 30, 2024 (09:19) / "Motley Fool" (by Cory Renauer)
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
These advantaged businesses have what it takes to keep raising their payouts.
In Article Trend: Somewhat-Bullish
March 28, 2024 (18:00) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Abbott Laboratories? - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories's ABT short percent of float has risen 12.16% since its last report. The company recently reported that it has 14.29 million shares sold short, which is 0.83% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
March 27, 2024 (16:25) / "Zacks Commentary" (by Zacks Equity Research)
Abbott's ( ABT ) Assert-IQ Cardiac Monitor Receives CE Mark
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
In Article Trend: Somewhat-Bullish
March 27, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment & Supplies Industry - Abbott Laboratories ( NYSE:ABT )
In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Abbott Laboratories ABT and its primary competitors in the ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Abbott Laboratories ( ABT ) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
March 25, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
Paris, France and Munich, Germany, March 25, 2024 - TRiCares SAS ( "TRiCares" ) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today is pleased to announce the appointment of Ahmed Elmouelhi as President & Chief Executive Officer ( CEO ) .
In Article Trend: Somewhat-Bullish
March 25, 2024 (00:55) / "Business Insider" (by Nicolás Jose Rodriguez)
Verano Holdings CIO To Share Insights Into Florida's Cannabis Boom At Benzinga Conference
Amidst the buzz of potential recreational legalization and federal cannabis rescheduling, comprehending cannabis stock dynamics is vital for investors. Florida's burgeoning market offers a unique chance for those poised to seize emerging opportunities.
In Article Trend: Bullish
March 25, 2024 (00:33) / "Benzinga" (by Nicolás Jose Rodriguez)
Verano Holdings CIO To Share Insights Into Florida's Cannabis Boom At Conference - Verano Holdings ( OTC:VRNOF )
Amidst the buzz of potential recreational legalization and federal cannabis rescheduling, comprehending cannabis stock dynamics is vital for investors. Florida's burgeoning market offers a unique chance for those poised to seize emerging opportunities. At Verano Holdings Inc.
In Article Trend: Bullish
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Point of Care Diagnostics Market is Expected to Reach $77.8 billion | MarketsandMarkets™
Chicago, March 22, 2024 ( GLOBE NEWSWIRE ) -- Point of Care Diagnostics market in terms of revenue was estimated to be worth $49.7 billion in 2023 and is poised to reach $77.8 billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028 according to a latest report published by ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (08:25) / "Motley Fool" (by Prosper Junior Bakiny)
Want Decades of Passive Income? 2 Stocks to Buy Now.
There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.
In Article Trend: Somewhat-Bullish
March 21, 2024 (15:00) / "Forbes" (by Bruce Japsen)
Diabetes Monitoring Apps Don't Deliver Meaningful Benefits, Report Says
Digital diabetes management tools "fail to deliver meaningful benefits to patients" while at the same time increasing the cost of healthcare to consumers, health insurers and taxpayers, a new report finds.
In Article Trend: Somewhat-Bullish
March 21, 2024 (13:09) / "CNBC" (by Jeff Marks)
We're buying more of this health-care company amid an overdone sell-off
The company has lost billions in market capitalization over the past few trading sessions.
In Article Trend: Neutral
March 19, 2024 (17:40) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain Abbott ( ABT ) Stock Now
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.
In Article Trend: Somewhat-Bullish
March 19, 2024 (15:43) / "CNBC" (by Morgan Chittum)
We're looking to buy more of this health care stock after an overblown selloff
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
In Article Trend: Neutral
March 19, 2024 (15:40) / "Benzinga" (by Globe Newswire)
Cardiovascular Implants Market Poised For Strong Growth, Reaching $34.5 Billion In 2028: Latest Report Unveils Insights As Per The Business Research Company's Cardiovascular Implants Global Market Report 2024
LONDON, March 19, 2024 ( GLOBE NEWSWIRE ) -- The global cardiovascular implants market is experiencing robust growth, as highlighted in the newest report "Cardiovascular Implants Market Global Report 2024", by The Business Research Company.
In Article Trend: Bullish
March 19, 2024 (14:16) / "Benzinga" (by Benzinga Insights)
What the Options Market Tells Us About Abbott Laboratories - Abbott Laboratories ( NYSE:ABT )
Financial giants have made a conspicuous bearish move on Abbott Laboratories. Our analysis of options history for Abbott Laboratories ABT revealed 19 unusual trades. Delving into the details, we found 5% of traders were bullish, while 94% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
March 18, 2024 (15:55) / "CNBC" (by Morgan Chittum)
Jim Cramer: It's not too late to buy this portfolio health-care stock after Friday's selloff
The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET.
In Article Trend: Somewhat-Bullish
March 18, 2024 (01:12) / "PR Newswire"
India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... - PR Newswire
India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... PR ...
In Article Trend: Somewhat-Bullish
March 17, 2024 (17:08) / "Benzinga" (by Globe Newswire)
Lutikizumab Clinical Trials Approved Bispecific Antibodies Market Insight
Delhi, March 17, 2024 ( GLOBE NEWSWIRE ) -- Global Bispecific Antibody Market Opportunity Insight 2029 Report Highlights: Global Market Forecast Till 2029: > USD 36 Billion Insight On Bispecific Antibodies In Clinical Trials: > 600 Bispecific Antibodies
In Article Trend: Neutral
March 15, 2024 (20:11) / "Benzinga" (by Globe Newswire)
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt Benckiser Group PLC Following $60 Million Baby Formula Verdict and Subsequent Stock Plummet - Reckitt Benckiser Group ( OTC:RBGLY )
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 15, 2024 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Reckitt Benckiser Group PLC ( "Reckitt" or the "Company" ) RBGLY investors that the law firm has initiated an investigation on ...
In Article Trend: Neutral
March 15, 2024 (17:48) / "Benzinga" (by Vandana Singh)
What's Going On With Abbott Laboratories Stock On Friday? - Abbott Laboratories ( NYSE:ABT )
An Illinois jury has issued a verdict compelling Reckitt Benckiser Group Plc's RBGLY RBGPF Mead Johnson to pay $60 million to the mother of a premature infant who tragically succumbed to necrotizing enterocolitis ( NEC ) after being fed the company's Enfamil baby formula.
In Article Trend: Neutral
March 15, 2024 (16:33) / "Investors Business Daily" (by ALLISON GATLIN)
Why Abbott's Formula Selloff Could Be A Buying Opportunity, Says Analyst
Abbott Stock Dives As Fellow Formula Maker Fined $60 Million Following Infant Death Investor's Business Daily ...
In Article Trend: Neutral
March 15, 2024 (14:50) / "CNBC" (by Zev Fima)
Here's why we're buying more of this healthcare stock after its Friday sell-off
When news breaks and hits the stock price - but likely not the earnings number - you're getting an actual discount.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:02) / "Zacks Commentary" (by Zacks Equity Research)
Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare
Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:38) / "Zacks Commentary" (by Bryan Hayes)
Medical Devices ETF Hits 52-Week High: Stocks to Watch
Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.
In Article Trend: Somewhat-Bullish
March 13, 2024 (16:04) / "Investors Business Daily" (by ALLISON GATLIN)
IBD Stock Of The Day Lingers In Buy Zone As Diabetes Play Eyes Obesity
Dexcom ( DXCM ) is Wednesday's IBD Stock Of The Day. Dexcom stock is lingering in a buy zone, bolstered by U.S. clearance of a new body-worn glucose monitor. The company developed Stelo, its newest continuous glucose monitor, for the roughly 25 million people in the U.S. with type 2 diabetes ...
In Article Trend: Neutral
March 13, 2024 (12:30) / "Benzinga" (by Globe Newswire)
Global In Vitro Toxicology Testing Market Size is projected to reach USD 28.19 billion by 2031, growing at a CAGR of 10.8%: Straits Research
New York, United States, March 13, 2024 ( GLOBE NEWSWIRE ) -- In Vitro toxicology testing is used to determine the toxicity of a substance on non-living cells or tissues. It is a crucial component of preclinical safety evaluation in the pharmaceutical, chemical, and regulatory industries.
In Article Trend: Somewhat-Bullish
March 13, 2024 (11:56) / "Zacks Commentary" (by Zacks Equity Research)
Roche ( RHHBY ) Launches AI-Based Predictive CGM Accu-Chek
Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:27) / "Zacks Commentary" (by Zacks Equity Research)
Bio-Rad ( BIO ) Suffers due to BioPharma Softness, Stiff Competition
Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
In Article Trend: Neutral
March 12, 2024 (02:30) / "PR Newswire" (by Research and Markets)
Japan In-Vitro Diagnostics Market Analysis Report 2024-2030: Strategic Partnerships Drive Innovations, Tumor Marker Testing Gains Momentum
Japan In-Vitro Diagnostics Market Analysis Report 2024-2030: Strategic Partnerships Drive Innovations, Tumor Marker ... PR ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (13:28) / "Motley Fool" (by Justin Pope)
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
There are some great companies at attractive prices in the lucrative pharmaceutical space.
In Article Trend: Somewhat-Bullish
March 11, 2024 (09:35) / "Motley Fool" (by Justin Pope)
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
These are some of the best-performing stocks in what's arguably society's most important industry.
In Article Trend: Somewhat-Bullish
March 9, 2024 (15:00) / "CNBC" (by Ashley Capoot)
Signos uses a glucose monitor patch and AI to help you eat healthier. Here's what it's like
Signos uses continuous glucose monitors, or CGMs, and an artificial intelligence-powered app to help people better understand their metabolisms.
In Article Trend: Neutral
March 8, 2024 (21:00) / "Benzinga" (by Benzinga Insights)
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories ABT has outperformed the market over the past 10 years by 1.21% on an annualized basis producing an average annual return of 11.92%. Currently, Abbott Laboratories has a market capitalization of $209.96 billion.
In Article Trend: Somewhat-Bullish
March 7, 2024 (17:27) / "Zacks Commentary" (by Zacks Equity Research)
Abbott ( ABT ) to Reduce Childhood Malnutrition With New Pact
Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
In Article Trend: Somewhat-Bullish
March 7, 2024 (10:00) / "Motley Fool" (by George Budwell)
Is Abbott Laboratories a Top Dividend Growth Stock to Buy Now?
Abbott Laboratories has been growing its dividend at a blistering pace. Is its stock a buy?
In Article Trend: Somewhat-Bullish
March 7, 2024 (07:31) / "Benzinga" (by Globe Newswire)
Biomarkers Market to Reach USD 125.6 billion by 2031, Projected a CAGR of 10.4%: Report Analysis by Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 07, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global biomarkers market is estimated to flourish at a CAGR of 10.4% from 2023 to 2031.
In Article Trend: Somewhat-Bullish
March 6, 2024 (21:48) / "Benzinga" (by Vandana Singh)
FDA Approval For DexCom's Stelo Opens Continuous Glucose Monitoring To Masses, Analyst Expects Competitive Pricing Against Abbott's - DexCom ( NASDAQ:DXCM )
Tuesday, the FDA approved DexCom Inc's DXCM Stelo Glucose Biosensor System as the first over-the-counter ( OTC ) continuous glucose monitor ( CGM ) . The Dexcom Stelo Glucose Biosensor System is an integrated CGM ( iCGM ) intended for anyone 18 years and older who does not use insulin.
In Article Trend: Somewhat-Bullish
March 6, 2024 (15:25) / "Investors Business Daily" (by Investor's Business Daily)
Dexcom Pops As It Enters A New CGM Market: Non-Diabetics
Dexcom Stock Pops After FDA Clears Its New Continuous Glucose Monitor Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:02) / "Benzinga" (by Benzinga Insights)
Sell Alert: John A. McCoy Jr. Cashes Out $55K In Abbott Laboratories Stock - Abbott Laboratories ( NYSE:ABT )
Revealing a significant insider sell on March 5, John A. McCoy Jr., Vice President at Abbott Laboratories ABT, as per the latest SEC filing. What Happened: Jr. opted to sell 472 shares of Abbott Laboratories, according to a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday.
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:02) / "Benzinga" (by Benzinga Insights)
Executive Vice President Of Abbott Laboratories Sold $94K In Stock - Abbott Laboratories ( NYSE:ABT )
Revealing a significant insider sell on March 5, Louis H Morrone, Executive Vice President at Abbott Laboratories ABT, as per the latest SEC filing. What Happened: A Form 4 filing with the U.S.
In Article Trend: Somewhat-Bullish
March 5, 2024 (15:02) / "Benzinga" (by Benzinga Insights)
Massive Insider Trade At Abbott Laboratories - Abbott Laboratories ( NYSE:ABT )
Making a noteworthy insider sell on March 5, Mary K Moreland, Executive Vice President at Abbott Laboratories ABT, is reported in the latest SEC filing. What Happened: Moreland's decision to sell 676 shares of Abbott Laboratories was revealed in a Form 4 filing with the U.S.
In Article Trend: Somewhat-Bullish
March 4, 2024 (14:45) / "Benzinga" (by Globe Newswire)
Global Meal Replacement Products Market Size is Projected to Reach USD 24.29 billion by 2030, Growing at a CAGR of 8.26%: Straits Research
New York, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- A pre-packaged, calorie-restricted food item known as a meal replacement product serves as a stand-in for a whole-food meal. The most popular forms of meal replacement items on the market include ready-to-eat foods, shakes, bars, and ...
In Article Trend: Somewhat-Bullish
March 3, 2024 (14:45) / "Motley Fool" (by Prosper Junior Bakiny)
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
There is a world of opportunities ahead for this healthcare giant.
In Article Trend: Somewhat-Bullish
March 1, 2024 (16:30) / "Benzinga" (by Benzinga Insights)
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today - Abbott Laboratories ( NYSE:ABT )
Abbott Laboratories ABT has outperformed the market over the past 10 years by 1.07% on an annualized basis producing an average annual return of 11.57%. Currently, Abbott Laboratories has a market capitalization of $206.49 billion.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website